RU2021121906A3 - - Google Patents

Download PDF

Info

Publication number
RU2021121906A3
RU2021121906A3 RU2021121906A RU2021121906A RU2021121906A3 RU 2021121906 A3 RU2021121906 A3 RU 2021121906A3 RU 2021121906 A RU2021121906 A RU 2021121906A RU 2021121906 A RU2021121906 A RU 2021121906A RU 2021121906 A3 RU2021121906 A3 RU 2021121906A3
Authority
RU
Russia
Application number
RU2021121906A
Other languages
Russian (ru)
Other versions
RU2021121906A (ru
RU2815314C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2021121906A publication Critical patent/RU2021121906A/ru
Publication of RU2021121906A3 publication Critical patent/RU2021121906A3/ru
Application granted granted Critical
Publication of RU2815314C2 publication Critical patent/RU2815314C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Storage Device Security (AREA)
RU2021121906A 2017-05-10 2018-05-02 Ингибиторы бета-лактамаз и их применение RU2815314C2 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762504523P 2017-05-10 2017-05-10
US62/504,523 2017-05-10
US201762551043P 2017-08-28 2017-08-28
US62/551,043 2017-08-28
US15/934,497 US10085999B1 (en) 2017-05-10 2018-03-23 Beta-lactamase inhibitors and uses thereof
US15/934,497 2018-03-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2019135891A Division RU2753401C2 (ru) 2017-05-10 2018-05-02 ИНГИБИТОРЫ β-ЛАКТАМАЗ И ИХ ПРИМЕНЕНИЕ

Publications (3)

Publication Number Publication Date
RU2021121906A RU2021121906A (ru) 2021-08-02
RU2021121906A3 true RU2021121906A3 (enExample) 2022-02-17
RU2815314C2 RU2815314C2 (ru) 2024-03-13

Family

ID=

Also Published As

Publication number Publication date
WO2018208557A1 (en) 2018-11-15
IL296379B2 (en) 2024-10-01
HUE062752T2 (hu) 2023-12-28
CA3062619A1 (en) 2018-11-15
US20240415847A1 (en) 2024-12-19
DK3625233T3 (da) 2023-08-28
MX2021008379A (es) 2021-08-11
NZ758353A (en) 2021-10-29
US10085999B1 (en) 2018-10-02
EP3625233B9 (en) 2023-10-25
BR112019023598A2 (pt) 2020-05-26
PT3625233T (pt) 2023-09-19
KR102411517B1 (ko) 2022-06-21
US20200297733A1 (en) 2020-09-24
FI3625233T3 (fi) 2023-09-05
ES2955871T9 (es) 2023-12-19
PL3625233T3 (pl) 2023-10-23
CA3153583A1 (en) 2018-11-15
MX385265B (es) 2025-03-18
EP3625233B1 (en) 2023-07-12
US10722521B2 (en) 2020-07-28
DK3625233T5 (da) 2024-02-05
US20230201218A1 (en) 2023-06-29
JP2020519684A (ja) 2020-07-02
HRP20230977T1 (hr) 2023-12-08
AU2018266566A1 (en) 2019-11-07
RS64547B1 (sr) 2023-09-29
AU2018266566B2 (en) 2020-06-04
RU2021121906A (ru) 2021-08-02
SG10202102306TA (en) 2021-04-29
CA3062619C (en) 2022-06-21
LT3625233T (lt) 2023-08-25
IL270330B2 (en) 2023-02-01
ES2955871T3 (es) 2023-12-07
RU2019135891A (ru) 2021-06-10
MX2019013260A (es) 2021-08-11
US20200046724A1 (en) 2020-02-13
CN110662746B (zh) 2022-08-19
SI3625233T1 (sl) 2023-10-30
AU2020227077B2 (en) 2022-10-20
FI3625233T5 (fi) 2023-12-12
AU2020227077A1 (en) 2020-09-24
IL270330A (enExample) 2019-12-31
SG11201909429VA (en) 2019-11-28
JP2021165298A (ja) 2021-10-14
RU2019135891A3 (enExample) 2021-06-10
KR20200004874A (ko) 2020-01-14
US10500211B2 (en) 2019-12-10
IL270330B (en) 2022-10-01
IL296379A (en) 2022-11-01
IL296379B1 (en) 2024-06-01
EP3625233A1 (en) 2020-03-25
JP6909924B2 (ja) 2021-07-28
US20190022102A1 (en) 2019-01-24
RS64547B9 (sr) 2024-02-29
RU2753401C2 (ru) 2021-08-16
CN110662746A (zh) 2020-01-07

Similar Documents

Publication Publication Date Title
BR122021000189A2 (enExample)
BR112019008823A2 (enExample)
BR112020006084A8 (enExample)
BR112019025875B1 (pt) Sistema de cilindro com estrutura de ocupação de movimento relativo
BR112020011860B1 (pt) Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho
BR112020008714B1 (pt) Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus
BR112020006992B1 (pt) Dispositivo de recolhimento e método para o recolhimento de uma embarcação
BR112019023976B1 (pt) Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde
BR112020003314B1 (pt) Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica
BR112020003112B1 (pt) Método de garantir a viabilidade de uma máquina para uma tarefa agendada
BR112020002577B1 (pt) Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo
BR112020001262B1 (pt) Processo para preparar uma composição de entrega de fármaco
BR112019016885B1 (pt) Remodelagem de imagem integrada e codificação de vídeo
BR112020001354B1 (pt) Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel
BR112019026818B1 (pt) Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador
BR102018011961B1 (pt) Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social
BR112019026880B1 (pt) Método de comunicação, método para receber dados, e, dispositivo
BR112019023944B1 (pt) Combinação farmacêutica para o tratamento de um câncer
BR112019021396B1 (pt) Processo para fabricação de pululano
BR112019016182B1 (pt) Método para diagnosticar risco de revisão relacionado a implante
BR112019017156B1 (pt) Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador
BR112019014017B1 (pt) Dispositivo de medição da quantidade de oxigênio presente em um gás, e, módulo de separação de ar
BR102017026429B1 (pt) Método de extração subsequente de ácidos graxos e dna genômico a partir de dípteros
BR112020006250B1 (pt) Primeira estação base e método de controle de estado em uma primeira estação base
BR112020007888B1 (pt) Terminal e método de radiocomunicação para um terminal